Anti-PD-1 or anti-CTLA-4 in first line therapy?
5 Nov 2015
Anti-PD-1 or anti-CTLA-4 in first line therapy?
Long response and long responders in melanoma immunology
Progress in targeted therapy of melanoma
Metastatic melanoma: Patient-reported outcomes from the KEYNOTE-002 study
Management of acute metastatic melanoma
How should we handle talimogene laherparepvec (T-VEC)?
New challenges in drug combination and strategies
Editor's choice for October 2015
Targeting N-RAS mutated tumours
HVEM expression in melanoma metastasis: prognosis correlation
Vemurafenib in patients with BRAF600 mutation–positive metastatic melanoma
ASTRO 2015 highlights: UK perspective